Opendata, web and dolomites

CAtALySt SIGNED

NeurescueTM: Computer- controlled aortic occlusion device for the treatment of cardiac arrest

Total Cost €

0

EC-Contrib. €

0

Partnership

0

Views

0

 CAtALySt project word cloud

Explore the words cloud of the CAtALySt project. It provides you a very rough idea of what is the project "CAtALySt" about.

episodes    burden    pressure    probability    barriers    germany    function    normal    post    samu    neurescuetm    aortic    occlusion    arrests    unrivalled    combines    roll    standard    proposition    aorta    aps    total    23    university    outside    predicted    assistance    portable    de    brain    roject    portability    proposes    surpass    cardiac    40    position    rate    algorithm    patient    below    blood    organs    business    2030    aggregated    catalyst    10    health    heart    premises    accuracy    resuscitation    ce    necker    revenue    rates    broad    with    sudden    survival    intervention    worldwide    safe    computer    window    perfusion    million    changing    commercial    paris    competitive    generation    adoption    marking    patients    234m    inside    2020    damage    france    solution    demonstration    company    device    works    medical    accurate    chu    holding    ready    price    vital    denmark    neur    validation    tissue    odense    sensor    hospital    public    united    synergy    introduction    run    incidence    clinical    light    time    gathering    market    radically    data    neurescue    profitable    projected    preservation    game    severe    89    critical    back    sca    building    emergency   

Project "CAtALySt" data sheet

The following table provides information about the project.

Coordinator
NEURESCUE APS 

Organization address
address: NJALSGADE 76
city: KOBENHAVN
postcode: 2300
website: n.a.

contact info
title: n.a.
name: n.a.
surname: n.a.
function: n.a.
email: n.a.
telephone: n.a.
fax: n.a.

 Coordinator Country Denmark [DK]
 Project website https://www.neurescue.com/home-eu/
 Total cost 2˙331˙787 €
 EC max contribution 1˙632˙251 € (70%)
 Programme 1. H2020-EU.3. (PRIORITY 'Societal challenges)
2. H2020-EU.2.3. (INDUSTRIAL LEADERSHIP - Innovation In SMEs)
3. H2020-EU.2.1. (INDUSTRIAL LEADERSHIP - Leadership in enabling and industrial technologies)
 Code Call H2020-SMEInst-2018-2020-2
 Funding Scheme SME-2
 Starting year 2018
 Duration (year-month-day) from 2018-08-01   to  2021-01-31

 Partnership

Take a look of project's partnership.

# participants  country  role  EC contrib. [€] 
1    NEURESCUE APS DK (KOBENHAVN) coordinator 1˙632˙251.00

Map

 Project objective

With a worldwide incidence expected to increase from 9,23 million cases by 2020 to 10,89 million cases by 2030, Sudden Cardiac Arrests (SCA) episodes are today recognized as a public health problem leading to severe brain tissue damage with survival rates below 10%. Neurescue Aps (NEUR) proposes to address the SCA burden by bringing to light a game changing solution - NeurescueTM – capable of extending the critical time window necessary to bring a SCA patient back to normal heart function, and therefore holding the potential to radically improve the emergency assistance provided to SCA patients, allowing for 20- 40% of increase in the survival rate of SCA patients. Due to an algorithm-run sensor technology which enables a safe and accurate computer-controlled aortic occlusion, NeurescueTM is a portable medical device that, not only increases the blood perfusion pressure necessary for vital organs preservation (i.e. brain and heart), but also works in synergy with standard resuscitation procedures increasing their probability of success. NeurescueTM is the only device in the market that combines portability with the accuracy required for a safe medical intervention (i.e. aorta occlusion) to SCA patients both inside and outside the hospital premises. With a price-competitive technology and with an unrivalled value proposition, NEUR is in a strong position to build a profitable business. Building on the project activities, NeurescueTM the device is projected to be ready for commercial roll-out by 2020 with a predicted total aggregated revenue for the company of over €234M throughout the 5 years post- roject. CAtALySt project aims to surpass the main market barriers associated with the market introduction of NeurescueTM, namely gathering data for CE-marking and broad clinical demonstration for market awareness and to ensure end-user medical adoption. Clinical validation will be held at Odense University Hospital in Denmark, and further clinical evidence generation at Hospital SAMU de Paris CHU Necker in France, a leading university hospital in Germany, and a leading university hospital in the United States.

Are you the coordinator (or a participant) of this project? Plaese send me more information about the "CATALYST" project.

For instance: the website url (it has not provided by EU-opendata yet), the logo, a more detailed description of the project (in plain text as a rtf file or a word file), some pictures (as picture files, not embedded into any word file), twitter account, linkedin page, etc.

Send me an  email (fabio@fabiodisconzi.com) and I put them in your project's page as son as possible.

Thanks. And then put a link of this page into your project's website.

The information about "CATALYST" are provided by the European Opendata Portal: CORDIS opendata.

More projects from the same programme (H2020-EU.3.;H2020-EU.2.3.;H2020-EU.2.1.)

MindTrack (2019)

Analysis of eye vergence responses for the early detection and monitoring of cognitive and mental disorders

Read More  

DeltaQon (2019)

IOT and cloud computing for online medical analysis service platform

Read More  

MHS (2019)

Metal Hydrides Hydrogen Storage

Read More